← Leaderboards
Jason T Kimata
Southwest Foundation For Biomedical Res
$11,879,127
Attributed
$12,792,122
Total exposure
30
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,792,122 · 30
By mechanism
R01$6,081,113 · 3
R21$1,872,347 · 4
R33$1,508,572 · 1
P51$1,476,658 · 17
P30$1,027,861 · 3
R56$825,571 · 2
Top collaborators
- Mahesh Mohan1 shared
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusInfectionVariantViralMacacaResearch PersonnelCd4 Positive T LymphocytesHiv-1Hiv InfectionsVirus DiseasesT-LymphocyteVirus ReplicationTissuesPropertyFundingResourcesUnited States National Institutes Of HealthTailFamily SuidaeFitnessInstitutionDendritic CellsMacrophageInsight
Grant awards (52)
Use of Focused ultrasound stimulated blood brain barrier opening for CNS HIV/SIV reservoir reduction$1,825,990
R01 · FY2025 · DA
Basic Science Core C$68,836
P30 · FY2025 · AI · contact PI
Basic Science Core C$115,221
P30 · FY2024 · AI · contact PI
Basic Science Core C$139,237
P30 · FY2023 · AI · contact PI
Basic Science Core C$253,304
P30 · FY2022 · AI · contact PI
Basic Science Core C$226,499
P30 · FY2021 · AI · contact PI
Bifunctional Chimeric Antigen Receptors for clearing HIV$490,909
R33 · FY2020 · AI · contact PI
Bifunctional Chimeric Antigen Receptors for clearing HIV$498,052
R33 · FY2019 · AI · contact PI
Bifunctional Chimeric Antigen Receptors for clearing HIV$519,611
R33 · FY2018 · AI · contact PI
Bifunctional Chimeric Antigen Receptors for clearing HIV$207,457
R21 · FY2017 · AI · contact PI
Bifunctional Chimeric Antigen Receptors for clearing HIV$264,750
R21 · FY2016 · AI · contact PI
Inhibition of HIV by GPI-anchored Antibody Derivatives$200,000
R01 · FY2015 · AI · contact PI
Replication and pathogenesis of pigtail-tropic HIV-1$510,275
R56 · FY2014 · AI · contact PI
Virology Core$224,764
P30 · FY2014 · AI · contact PI
Inhibition of HIV by GPI-anchored Antibody Derivatives$200,000
R01 · FY2014 · AI · contact PI
Inhibition of HIV by GPI-anchored Antibody Derivatives$200,000
R01 · FY2013 · AI · contact PI
HIV-1 Resistance to Type I Interferon in Macaques$195,625
R21 · FY2013 · AI · contact PI
HIV-1 Resistance to Type I Interferon in Macaques$234,750
R21 · FY2012 · AI · contact PI
REPLICATIVE FITNESS OF SIV VARIANTS$133,357
P51 · FY2011 · RR · contact PI
INNATE RESISTANCE TO SIV INFECTION$23,693
P51 · FY2011 · RR · contact PI
Replicative fitness of SIV variants$331,620
R01 · FY2010 · AI · contact PI
Toward an HIV-1 macaque model$151,965
R21 · FY2010 · AI · contact PI
INNATE RESISTANCE TO SIV INFECTION$9,595
P51 · FY2010 · RR · contact PI
Replicative fitness of SIV variants$527,642
R01 · FY2009 · AI · contact PI
Toward an HIV-1 macaque model$300,000
R21 · FY2009 · AI · contact PI
REPLICATIVE FITNESS OF SIV VARIANTS$70,055
P51 · FY2009 · RR · contact PI
INNATE RESISTANCE TO SIV INFECTION$9,904
P51 · FY2009 · RR · contact PI
Replicative fitness of SIV variants$512,273
R01 · FY2008 · AI · contact PI
REPLICATIVE FITNESS OF SIV VARIANTS$53,161
P51 · FY2008 · RR · contact PI
INNATE RESISTANCE TO SIV INFECTION$8,564
P51 · FY2008 · RR · contact PI
Replicative fitness of SIV variants$506,985
R01 · FY2007 · AI · contact PI
REPLICATIVE FITNESS OF SIV VARIANTS$110,351
P51 · FY2007 · RR · contact PI
DEVELOPMENT OF A SHIV-RT MODEL$13,498
P51 · FY2007 · RR · contact PI
Replicative fitness of SIV variants$397,543
R01 · FY2006 · AI · contact PI
REPLICATIVE FITNESS OF SIV VARIANTS$99,115
P51 · FY2006 · RR · contact PI
DEVELOPMENT OF A SHIV-RT MODEL$87,708
P51 · FY2006 · RR · contact PI
Replicative fitness of SIV variants$315,296
R56 · FY2005 · AI
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$82,955
P51 · FY2005 · RR
DEVELOPMENT OF A SHIV-RT MODEL$73,411
P51 · FY2005 · RR
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$263,375
R01 · FY2004 · AI
STRATEGIES TO PREVENT SIV BINDING TO MACAQUE DC-SIGN$113,894
P51 · FY2004 · RR
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$102,471
P51 · FY2004 · RR
STRATEGIES TO PREVENT SIV BINDING TO MACAQUE DC-SIGN$231,472
P51 · FY2003 · RR
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$231,472
P51 · FY2003 · RR
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$188,125
R01 · FY2003 · AI
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$80,000
R01 · FY2003 · AI
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$287,000
R01 · FY2002 · AI
Strategies to Prevent SIV Binding to Macaque DC-SIGN$258,900
R21 · FY2002 · AI
PATHOGENESIS OF A NOVEL LYMPH NODE-DERIVED SIV$282,520
R01 · FY2001 · AI
Strategies to Prevent SIV Binding to Macaque DC-SIGN$258,900
R21 · FY2001 · AI
PATHOGENESIS OF A NOVEL LYMPH NODE DERIVED SIV$278,040
R01 · FY2000 · AI
PATHOGENESIS OF NOVEL LYMPH NODE DERIVED SIV$21,982
P51 · FY2000 · RR